Dr Anne-Cécile Petit is Associate Professor (MCU-PH) of embryology at Université Paris Cité and psychiatrist at GHU Paris – hôpital Sainte-Anne.
Her research focuses on understanding the pathophysiological mechanisms of mood disorders, particularly depression, by seeking to understand the links between inflammatory mechanisms and brain dysfunction.
Click to view graph
Connections
Click to view timeline
Timeline
About
Projects
Publications
Download-
2021Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine., Int J Antimicrob Agents 2021 Mar; 57(3): 106274.
-
2020[The next psychoactive drugs: From imipramine to ketamine]., Bull Acad Natl Med 2020 Dec; 204(9): 1034-1042.
-
2020The next psychoactive drugs: From imipramine to ketamine., Bull Acad Natl Med 2020 Dec; 204(9): e169-e177.
-
2020Repurposing chlorpromazine to treat COVID-19: The reCoVery study., Encephale 2020 Jun; 46(3): 169-172.
-
2020[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]., Encephale 2020 Jun; 46(3S): S35-S39.
-
2020Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?, J Clin Psychopharmacol 2020 ; 40(6): 636-638.
-
2019Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine., Brain Behav Immun. 2019 Jun 28.
-
2018The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients, Prog. Neuropsychopharmacol. Biol. Psychiatry 2018 Feb;81:74-79.
-
2017No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patients, Pharmacogenomics 2017 Mar;18(4):349-357.
-
2016Mother’s Emotional and Posttraumatic Reactions after a Preterm Birth: The Mother-Infant Interaction Is at Stake 12 Months after Birth, PLoS ONE 2016;11(3):e0151091.
-
+View full list of publications